Basilea Pharmaceutica AG's antibiotic ceftobiprole failed for the third time to clear FDA review due to data integrity issues, news that sent shares falling 15 percent but could give the Swiss company more ammunition in its ongoing arbitration process claiming damages against partner Johnson & Johnson. (BioWorld Today) Read More
